SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Avacta reports positive preclinical results for dual-payload cancer candidate AVA6207

Life sciences company Avacta Therapeutics (AIM:AVCT) on Thursday reported new preclinical data showi

AVACTA

Related stories